(S)-2-(Boc-Amino)non-8-Enoic Acid CAS 300831-21-4 Purity >98.0% (GC) ee >99.0% Paritaprevir Intermediate Factory

Maelezo Fupi:

Jina: (S)-2-(Boc-Amino)asidi isiyo ya 8-Enoic

CAS: 300831-21-4

Usafi: >98.0% (GC)

yaani: >99.0%

Muonekano: Kioevu cha Brown

Wastani wa Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Tutumie barua pepe

Maelezo ya Bidhaa

Bidhaa Zinazohusiana

Lebo za Bidhaa

Maelezo:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Sifa za Kemikali:

Jina la Kemikali	(S)-2-(Boc-Amino) Asidi ya Enoic isiyo na 8
Visawe	(S)-2-(tert-Butoxycarbonylamino)asidi isiyo na 8-Enoic;(S)-2-(Boc-Amino)-8-Asidi isiyo na Nonenoic;(2S)-2-[(2-Methylpropan-2-yl)oxycarbonylamino]asidi isiyo na 8-Enoic;(2S)-2-{[(tert-Butoxy)carbonyl]amino}non-8-Enoic Acid
Nambari ya CAS	300831-21-4
Nambari ya CAT	RF-CC347
Hali ya Hisa	Katika Hisa
Mfumo wa Masi	C14H25NO4
Uzito wa Masi	271.35
Msongamano	1.035±0.06 g/cm3
Chapa	Ruifu Chemical

Vipimo:

Kipengee	Vipimo
Mwonekano	Kioevu cha Brown
Njia ya Usafi / Uchambuzi	>98.0% (GC)
ee	>99.0%
Kiwango cha Mtihani	Kiwango cha Biashara
Matumizi	Wastani wa Paritaprevir (CAS: 1216941-48-8)

Kifurushi na Hifadhi:

Kifurushi: Chupa ya Fluorinated, 25kg/Ngoma, au kulingana na mahitaji ya mteja

Hali ya Uhifadhi:Hifadhi kwenye vyombo vilivyofungwa mahali pa baridi na kavu;Kinga kutoka kwa mwanga na unyevu

Manufaa:

Maswali Yanayoulizwa Mara kwa Mara:

Maombi:

(S)-2-(Boc-Amino)asidi isiyo-8-Enoic (CAS: 300831-21-4) inaweza kutumika kama kiungo cha kati katika usanisi wa Paritaprevir (CAS: 1216941-48-8) na analogi zinazohusiana.Paritaprevir ni kizuizi cha kizazi cha pili cha NS3/4A protease, ni sehemu ya tiba ya mchanganyiko wa virusi vya homa ya ini ya C ya mdomo, isiyo na interferon iliyotengenezwa na Enanta Pharmaceuticals na AbbVie.Tembe ya dozi isiyobadilika ya Paritaprevir, Ombitasvir na Ritonavir iliyochukuliwa pamoja na Dasabuvir iliidhinishwa kwa matibabu ya aina sugu ya HCV genotype 1 nchini Marekani na EU mwaka wa 2014, na kuidhinishwa zaidi kwa ajili ya matibabu ya maambukizo sugu ya genotype 4 ya HCV bila cirrhosis na Marekani. FDA mnamo 2015.